Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Allison

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Biomedicines|July 27, 2022
Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of ActionSimon J Allison
Cell Cycle (Georgetown, Tex.)|September 13, 2011
SIRT1, p53 and mitotic chromosomesJo Milner, Simon J Allison
Molecular Therapy. Nucleic Acids|January 9, 2014
RNA Interference by Single- and Double-stranded siRNA With a DNA Extension Containing a 3' Nuclease-resistant Mini-hairpin StructureSimon J Allison, Jo Milner
Cancer Research|October 30, 2003
Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidySimon J Allison, Jo Milner
Cell Cycle (Georgetown, Tex.)|October 25, 2007
SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathwaysSimon J Allison, Jo Milner
Carcinogenesis|July 3, 2004
Remodelling chromatin on a global scale: a novel protective function of p53Simon J Allison, Jo Milner
Aging|February 17, 2010
Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cellsSimon J Allison, Ming Jiang, Jo Milner
Pharmacology Research & Perspectives|December 15, 2023
Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cellsKartheek Sooda, Simon J Allison, Farideh A Javid
Open Biology|November 22, 2013
Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activityJohn R P Knight, Simon J Allison, Jo Milner
Biochemical Society Transactions|June 24, 2020
Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic targetHollie B S Griffiths, Courtney Williams, Sarah J King, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Biomedicines|July 27, 2022
Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of ActionSimon J Allison
Cell Cycle (Georgetown, Tex.)|September 13, 2011
SIRT1, p53 and mitotic chromosomesJo Milner, Simon J Allison
Molecular Therapy. Nucleic Acids|January 9, 2014
RNA Interference by Single- and Double-stranded siRNA With a DNA Extension Containing a 3' Nuclease-resistant Mini-hairpin StructureSimon J Allison, Jo Milner
Cancer Research|October 30, 2003
Loss of p53 has site-specific effects on histone H3 modification, including serine 10 phosphorylation important for maintenance of ploidySimon J Allison, Jo Milner
Cell Cycle (Georgetown, Tex.)|October 25, 2007
SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathwaysSimon J Allison, Jo Milner
Carcinogenesis|July 3, 2004
Remodelling chromatin on a global scale: a novel protective function of p53Simon J Allison, Jo Milner
Aging|February 17, 2010
Oncogenic viral protein HPV E7 up-regulates the SIRT1 longevity protein in human cervical cancer cellsSimon J Allison, Ming Jiang, Jo Milner
Pharmacology Research & Perspectives|December 15, 2023
Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cellsKartheek Sooda, Simon J Allison, Farideh A Javid
Open Biology|November 22, 2013
Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activityJohn R P Knight, Simon J Allison, Jo Milner
Biochemical Society Transactions|June 24, 2020
Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic targetHollie B S Griffiths, Courtney Williams, Sarah J King, et al.
Pageof 4